AD1208 / Avelos Therap - LARVOL DELTA

Microtubule-associated serine/threonine kinase-likeinhibitor, AD1208, as a novel cancer therapeutics (AACR 2024) - "Currently, AD1208 is being conducted in IND enabling GLP-Tox studies, including genotoxicity, mutagenicity, safety pharmacology as well as in vivo safety studies. Taken together, AD1208 is identified as a novel and selective MASTL inhibitor exhibiting significant therapeutic potential to be a development candidate."

Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Solid Tumor • BRCA • CDK1

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=36 | Recruiting | Sponsor: Avelos Therapeutics Inc.

New P1/2 trial • Oncology • Solid Tumor

AVELOS THERAPEUTICS ANNOUNCES KRW 17 BILLION SERIES B FUNDING ROUND, SURPASSING KRW 30 BILLION TOTAL RAISED (PRNewswire) - "Avelos Therapeutics...recently completed a successful Series B funding round totaling KRW 17 billion (approximately $12.3 million USD) on April 30....An oral medication, AD1208 demonstrates excellent efficacy in selectively inhibiting cancer cells in both laboratory and animal testing. Clinical trials are scheduled to start in the second half of the year, following preclinical toxicity study, using funding from the Series B investment."

Financing • New trial • Preclinical • Oncology